For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rivaroxaban - Prevention of atherothrombotic events - coronary or peripheral artery disease
PAD Profile : Rivaroxaban - Prevention of atherothrombotic events - coronary or peripheral artery disease
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
- Atrial fibrillation
- VTE prevention post hip/knee replacement
- Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
- Prevention of atherothrombotic events - Acute Coronary Syndrome
Additional Documents
Committee Recommendations
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree that rivaroxaban is a treatment option for people with coronary or peripheral artery disease in line with NICE TA 607.
Rivaroxaban will be given a GREEN traffic light status for this indication
The APC recognises that the difference between the benefits and risks is small, but the APC supports prescribing for PAD or CAD, in those patients where the clinicians have identified (with shared decision making, and as part of a routine review) that the patient is likely to benefit from treatment with rivaroxaban.